No Data
No Data
Express News | Black Diamond Therapeutics: Results From Phase 1 Dose Escalation Trial of Bdtx-1535 in GBM Patients Demonstrated Favorable Safety and Tolerability
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
PDF Version CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target fami
Black Diamond Theraptcs Is Maintained at Buy by HC Wainwright & Co.
Black Diamond Theraptcs Is Maintained at Buy by HC Wainwright & Co.
Black Diamond Therapeutic Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 100% HC Wainwright & Co. $12 → $11 Maintains Buy 04/08/2024 190.91% Wedbush $10 → $16 Maintains
Buy Rating Affirmed for Black Diamond Therapeutics Amid Strong Financials and Promising Clinical Trials
Express News | Black Diamond Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $11 From $12
No Data